CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
OPERATING ACTIVITIES:
Net loss	$ (363,475)	$ (33,366)	$ (272,107)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	47,824	56,309	55,594
Deferred income tax expense (benefit)	117,890	(8,585)	(87,242)
Share-based compensation	9,037	10,216	9,027
Asset impairment charges	216,550	34,448	375,381
Loss (gain) on sale/disposal of assets	171	(159)	1,559
Loss on extinguishment of debt	10,341	2,145	448
Accrual of payment-in-kind interest	3,642
Amortization of debt discount and other debt issuance costs	10,146	14,336	17,641
Provision for inventory write-downs	24,328	10,341	21,765
Other noncash expenses	1,021	1,969	2,579
Changes in assets and liabilities which provided (used) cash:
Accounts receivable, net	26,854	39,064	84,949
Inventories	8,994	(9,237)	(24,101)
Income taxes receivable/payable	(20,437)	(14,465)	18,319
Other assets	2,509	4,095	2,643
Rebates payable	(19,150)	(8,000)	(3,225)
Royalties payable	(7,084)	4,648	10,260
Restructuring liability	(19)	(2,288)	(4,391)
Operating lease liability	(194)	(1,464)
Accounts payable	(2,950)	19,042	(43,274)
Accrued expenses	(1,885)	2,213	(1,620)
Accrued payroll and payroll-related expenses	(5,624)	(3,620)	12,105
Other liabilities	2,362	(1,628)
Net cash provided by operating activities	60,851	116,014	176,310
INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(10,415)	(18,330)	(24,340)
Proceeds from sale of property, plant and equipment	114	7,380	14,450
Proceeds from sale of outstanding loan to Variable Interest Entity ("VIE")			5,600
Advance to VIE		(250)
Purchases of intangible assets	(4,500)	(28,800)	(3,000)
Net cash used in investing activities	(14,801)	(40,000)	(7,290)
FINANCING ACTIVITIES:
Proceeds from issuance of long-term debt	356,225	86,250
Purchase of capped call		(7,072)
Repayments of long-term debt	(437,926)	(146,700)	(126,743)
Proceeds from issuance of stock	664	998	1,180
Payment of debt issuance costs	(10,088)	(3,489)	(1,102)
Purchase of treasury stock	(1,047)	(1,909)	(592)
Net cash used in financing activities	(92,172)	(71,922)	(127,257)
Effect on cash and cash equivalents of changes in foreign exchange rates	79	(12)	(100)
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(46,043)	4,080	41,663
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	144,329	140,249	98,586
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	98,286	144,329	140,249
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	34,859	51,928	66,750
Income taxes paid (refunded)	(36,830)	7,787	(4,641)
Andor Pharmaceuticals, LLC ("Andor") License Agreement acquisition			16,000
Accrued purchases of property, plant and equipment	1,809	$ 2,295	$ 765
Issuance of warrant in connection with Second Lien Credit Facility	$ 24,375